Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines, Inc.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance.  Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders.We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-26.54M -	-35.51M 33.83%	-61.82M 74.08%	-167.06M 170.24%	-214.03M 28.11%	-123.28M 42.40%
depreciation and amortization	1K -	37K 3,600%	50K 35.14%	182K 264%	419K 130.22%	432K 3.10%
deferred income tax	3.65M -			2.09M -		8.86M -
stock based compensation	579K -	668K 15.37%	5.21M 680.09%	22.69M 335.48%	28.59M 26.00%	24.86M 13.07%
change in working capital	1.46M -	745K 48.94%	3.24M 334.90%	16.13M 397.93%	-1.78M 111.04%	-14.03M 687.87%
accounts receivables
inventory
accounts payables	1.67M -	-837K 150.21%	960K 214.70%	7.27M 656.98%	3.89M 46.44%	-8.86M 327.52%
other working capital	-208K -	1.58M 860.58%	2.28M 44.12%	8.87M 288.86%	-5.67M 163.99%	-5.18M 8.74%
other non cash items	127K -	642K 405.51%	696K 8.41%	1.41M 102.87%	1.75M 24.29%	-7.97M 554.19%
net cash provided by operating activities	-20.72M -	-33.42M 61.29%	-52.62M 57.46%	-124.55M 136.69%	-185.04M 48.56%	-111.14M 39.94%
investments in property plant and equipment	-63K -	-103K 63.49%	4K 103.88%	-1.05M 26,350%	-444K 57.71%	-50K 88.74%
acquisitions net				139.47M -	-97.33M 169.79%
purchases of investments				-164.17M -	-83.02M 49.43%
sales maturities of investments				24.70M -	180.35M 630.18%	39M 78.38%
other investing activites				-139.47M -	97.33M 169.79%
net cash used for investing activites	-63K -	-103K 63.49%	4K 103.88%	-140.52M 3,513,100%	96.89M 168.95%	38.95M 59.80%
debt repayment		-633K -	-696K 9.95%	-763K 9.63%	-811K 6.29%	-1.00M 23.92%
common stock issued		60.39M -	200.89M 232.66%	105.71M 47.38%	9.56M 90.96%	91.59M 857.98%
common stock repurchased			-30M -		-260K -
dividends paid			-696K -		-811K -
other financing activites	37.80M -	633K 98.33%	134.92M 21,214.69%	2.63M 98.05%	2.79M 5.73%	1.28M 53.91%
net cash used provided by financing activities	37.80M -	60.39M 59.74%	304.42M 404.10%	107.59M 64.66%	10.46M 90.27%	91.87M 777.89%
effect of forex changes on cash			-4K -
net change in cash	17.02M -	26.86M 57.84%	251.79M 837.25%	-157.49M 162.55%	-77.69M 50.67%	19.68M 125.34%
cash at beginning of period	1.53M -	18.55M 1,112.42%	45.41M 144.82%	297.21M 554.43%	139.72M 52.99%	62.03M 55.60%
cash at end of period	18.55M -	45.41M 144.82%	297.21M 554.43%	139.72M 52.99%	62.03M 55.60%	81.72M 31.73%
operating cash flow	-20.72M -	-33.42M 61.29%	-52.62M 57.46%	-124.55M 136.69%	-185.04M 48.56%	-111.14M 39.94%
capital expenditure	-63K -	-103K 63.49%	4K 103.88%	-1.05M 26,350%	-444K 57.71%	-50K 88.74%
free cash flow	-20.78M -	-33.52M 61.29%	-52.62M 56.96%	-125.60M 138.70%	-185.49M 47.68%	-111.19M 40.06%

PRAX

NASDAQ:PRAX

Praxis Precision Medicines

Last Close

57.54

26/07 20:00

Market Cap

819.81M

Beta: 3.01

Volume Today

145.59K

Avg: 1.66M

PE Ratio

−41.39

PFCF: −3.16

Preview